AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating reissued by research analysts at Shore Capital in a report released on Tuesday, StockTargetPrices.com reports.
Several other analysts also recently issued reports on AZN. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 5,500 ($67.93) price target on shares of AstraZeneca plc in a report on Tuesday. Liberum Capital reaffirmed a “buy” rating and issued a GBX 5,100 ($62.99) price target on shares of AstraZeneca plc in a report on Tuesday. Berenberg Bank upped their price target on shares of AstraZeneca plc from GBX 5,450 ($67.31) to GBX 5,670 ($70.03) and gave the company a “buy” rating in a report on Monday. HSBC Holdings plc reduced their price target on shares of AstraZeneca plc from GBX 4,700 ($58.05) to GBX 4,500 ($55.58) and set a “hold” rating on the stock in a report on Tuesday, February 7th. Finally, Barclays PLC assumed coverage on shares of AstraZeneca plc in a report on Wednesday, March 8th. They issued an “overweight” rating and a GBX 6,000 ($74.10) price target on the stock. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. AstraZeneca plc presently has an average rating of “Hold” and a consensus target price of GBX 5,018.36 ($61.98).
AstraZeneca plc (LON:AZN) opened at 4900.00 on Tuesday. The firm’s market cap is GBX 62.00 billion. The firm has a 50 day moving average of GBX 4,617.49 and a 200 day moving average of GBX 4,602.58. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.
The firm also recently disclosed a dividend, which was paid on Monday, March 20th. Stockholders of record on Thursday, February 16th were given a GBX 150.20 ($1.86) dividend. The ex-dividend date was Thursday, February 16th. This represents a dividend yield of 3.52%. This is a positive change from AstraZeneca plc’s previous dividend of $68.70.
var userip;Your IP Address: document.write(userip);
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.